Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Health stock Park Medi World jumps 10% despite stock market crash. Emkay sees over 25% more upside - Mint
Health stock Park Medi World jumps 10% despite stock market crash. Emkay sees over 25% more upsideMint
AksharChem (India) Ltd leads gainers in 'B' group
Jeena Sikho Lifecare Ltd, JHS Svendgaard Retail Ventures Ltd, Emkay Global Financial Services Ltd and John Cockerill India Ltd are among the other gainers in the BSE's 'B' group today, 03 June 2026.
Blue Jet Healthcare gains 8% post Q4; analysts split on near-term prospects
Emkay Global has retained its 'Reduce' rating, while Motilal Oswal has maintained its 'Buy' stance, reflecting contrasting expectations on recovery in key business segments and the margin trajectory
Smallcap winners! Wockhardt, Tata Tech, CAMS, other stocks rally up to 11% despite overall market weakness
Smallcap stocks outperformed on Tuesday despite weak broader markets, with Wockhardt, Tata Tech and CAMS gaining up to 11% on strong Q4 earnings. While Nifty 50 slipped below 24,000 amid global concerns, improving momentum and technical indicators signal potential continued strength in the smallcap segment, according to Emkay.
Buy Star Health; target of Rs 650: Emkay Global Financial
Emkay Global Financial is bullish on Star Health has recommended buy rating on the stock with a target price of Rs 650 in its research report dated April 29, 2026.
Buy Vijaya Diagnostic; target of Rs 1400: Emkay Global Financial
Emkay Global Financial is bullish on Vijaya Diagnostic has recommended buy rating on the stock with a target price of Rs 1400 in its research report dated Jun 24, 2026.
Buy Ipca Laboratories; target of Rs 1800: Emkay Global Financial
Emkay Global Financial is bullish on Ipca Laboratories has recommended buy rating on the stock with a target price of Rs 1800 in its research report dated June 02, 2026.
Buy Park Medi World; target of Rs 350: Emkay Global Financial
Emkay Global Financial is bullish on Park Medi World has recommended buy rating on the stock with a target price of Rs 350 in its research report dated Jun 18, 2026.
Vijaya Diagnostic gains over 3% as Emkay reiterates buy, sees strong growth across key markets
The stock climbed as much as 5 percent to an intraday high of Rs 1,375.30 before trading at Rs 1,358.80, up 3.5 percent, in afternoon trade